P Laakkonen

Summary

Affiliation: University of Helsinki
Country: Finland

Publications

  1. ncbi Peptide targeting of tumor lymph vessels
    Pirjo Laakkonen
    Molecular Cancer Biology Research Program and Institute of Biomedicine, Biomedicum Helsinki, P O Box 63, Haartmaninkatu 8, 00014 University of Helsinki, Finland
    Ann N Y Acad Sci 1131:37-43. 2008
  2. ncbi [Ligandomics--a tool for the development of targeted treatments]
    Kimmo Porkka
    HUS, , hematologian klinikka
    Duodecim 118:1185-92. 2002
  3. ncbi Development of peptides specifically modulating the activity of KLK2 and KLK3
    Hannu Koistinen
    Department of Clinical Chemistry, Biomedicum Helsinki, University of Helsinki and Helsinki University Central Hospital, 00014 Helsinki, Finland
    Biol Chem 389:633-42. 2008
  4. ncbi The effects of palmitoylation on membrane association of Semliki forest virus RNA capping enzyme
    P Laakkonen
    Institute of Biotechnology, University of Helsinki, P O Box 56, Viikinkaari 9, FIN 00014 Helsinki, Finland
    J Biol Chem 271:28567-71. 1996
  5. ncbi Critical residues of Semliki Forest virus RNA capping enzyme involved in methyltransferase and guanylyltransferase-like activities
    T Ahola
    Institute of Biotechnology, University of Helsinki, Finland
    J Virol 71:392-7. 1997
  6. ncbi Effects of palmitoylation of replicase protein nsP1 on alphavirus infection
    T Ahola
    Research Program in Cellular Biotechnology, Institute of Biotechnology, FIN 00014 University of Helsinki, Finland
    J Virol 74:6725-33. 2000
  7. ncbi Antiangiogenic properties of prostate-specific antigen (PSA)
    Johanna M Mattsson
    Department of Clinical Chemistry, Biomedicum, University of Helsinki and Helsinki University Central Hospital, Helsinki, Finland
    Scand J Clin Lab Invest 69:447-51. 2009
  8. ncbi Kaposi's sarcoma herpesvirus lytic replication compromises apoptotic response to p53 reactivation in virus-induced lymphomas
    G Sarek
    Institute of Biotechnology and Research Programs Unit, Genome Scale Biology, Biomedicum Helsinki, Institute of Biomedicine, University of Helsinki, Helsinki, Finland
    Oncogene 32:1091-8. 2013
  9. ncbi Tumour-homing peptides: tools for targeting, imaging and destruction
    J Enbäck
    Molecular Cancer Biology Research Program and Institute of Biomedicine, Biomedicum Helsinki, University of Helsinki, Finland
    Biochem Soc Trans 35:780-3. 2007
  10. ncbi A heparan sulfate-targeted conditionally replicative adenovirus, Ad5.pk7-Delta24, for the treatment of advanced breast cancer
    T Ranki
    Cancer Gene Therapy Group, Rational Drug Design Program and Haartman Institute, University of Helsinki, Helsinki, Finland
    Gene Ther 14:58-67. 2007

Collaborators

Detail Information

Publications22

  1. ncbi Peptide targeting of tumor lymph vessels
    Pirjo Laakkonen
    Molecular Cancer Biology Research Program and Institute of Biomedicine, Biomedicum Helsinki, P O Box 63, Haartmaninkatu 8, 00014 University of Helsinki, Finland
    Ann N Y Acad Sci 1131:37-43. 2008
    ....
  2. ncbi [Ligandomics--a tool for the development of targeted treatments]
    Kimmo Porkka
    HUS, , hematologian klinikka
    Duodecim 118:1185-92. 2002
  3. ncbi Development of peptides specifically modulating the activity of KLK2 and KLK3
    Hannu Koistinen
    Department of Clinical Chemistry, Biomedicum Helsinki, University of Helsinki and Helsinki University Central Hospital, 00014 Helsinki, Finland
    Biol Chem 389:633-42. 2008
    ..In this review we summarize the possible roles of KLK3 and KLK2 in prostate cancer and then concentrate on the development of peptides that modulate the activity of these proteases...
  4. ncbi The effects of palmitoylation on membrane association of Semliki forest virus RNA capping enzyme
    P Laakkonen
    Institute of Biotechnology, University of Helsinki, P O Box 56, Viikinkaari 9, FIN 00014 Helsinki, Finland
    J Biol Chem 271:28567-71. 1996
    ..These results indicate that the acylation of Nsp1 was not needed for its targeting to the plasma membrane, but it was necessary for the migration to the filopodial extensions of the plasma membrane...
  5. ncbi Critical residues of Semliki Forest virus RNA capping enzyme involved in methyltransferase and guanylyltransferase-like activities
    T Ahola
    Institute of Biotechnology, University of Helsinki, Finland
    J Virol 71:392-7. 1997
    ..Secondary structure predictions of nsP1 and other proteins of the superfamily place these residues in positions corresponding to AdoMet-binding sites of cellular methyltransferases, suggesting that they all may be structurally related...
  6. ncbi Effects of palmitoylation of replicase protein nsP1 on alphavirus infection
    T Ahola
    Research Program in Cellular Biotechnology, Institute of Biotechnology, FIN 00014 University of Helsinki, Finland
    J Virol 74:6725-33. 2000
    ..The SFV mutant was apathogenic in mice: it caused blood viremia, but no infectious virus was detected in the brain...
  7. ncbi Antiangiogenic properties of prostate-specific antigen (PSA)
    Johanna M Mattsson
    Department of Clinical Chemistry, Biomedicum, University of Helsinki and Helsinki University Central Hospital, Helsinki, Finland
    Scand J Clin Lab Invest 69:447-51. 2009
    ..Taken together, these studies suggest that PSA exerts antiantiogenic activity related to its enzymatic activity. Thus it might be associated with the slow growth of prostate cancer...
  8. ncbi Kaposi's sarcoma herpesvirus lytic replication compromises apoptotic response to p53 reactivation in virus-induced lymphomas
    G Sarek
    Institute of Biotechnology and Research Programs Unit, Genome Scale Biology, Biomedicum Helsinki, Institute of Biomedicine, University of Helsinki, Helsinki, Finland
    Oncogene 32:1091-8. 2013
    ..These results highlight the potential impact of activation of viral lytic replication on disease progression and response to treatment in KSHV-induced lymphomas...
  9. ncbi Tumour-homing peptides: tools for targeting, imaging and destruction
    J Enbäck
    Molecular Cancer Biology Research Program and Institute of Biomedicine, Biomedicum Helsinki, University of Helsinki, Finland
    Biochem Soc Trans 35:780-3. 2007
    ..These peptides appear to be able to concentrate in the target tissue, making them particularly efficient delivery vectors for the targeting of drugs, other therapeutic moieties and imaging agents...
  10. ncbi A heparan sulfate-targeted conditionally replicative adenovirus, Ad5.pk7-Delta24, for the treatment of advanced breast cancer
    T Ranki
    Cancer Gene Therapy Group, Rational Drug Design Program and Haartman Institute, University of Helsinki, Helsinki, Finland
    Gene Ther 14:58-67. 2007
    ..These results suggest utility of Ad5.pK7-Delta24 and the orthotopic model for further translational studies...
  11. ncbi Vascular endothelial growth factor receptor 3 is involved in tumor angiogenesis and growth
    Pirjo Laakkonen
    Molecular Cancer Biology Research Program and Ludwig Institute for Cancer Research, Biomedicum Helsinki, Haartman Institute and Helsinki University Central Hospital, University of Helsinki, Finland
    Cancer Res 67:593-9. 2007
    ..These results suggest that the VEGFR-3 pathway contributes to tumor angiogenesis and that effective inhibition of tumor progression may require the inhibition of multiple angiogenic targets...
  12. ncbi Structural characterization and anti-angiogenic properties of prostate-specific antigen isoforms in seminal fluid
    Johanna M Mattsson
    Department of Clinical Chemistry, Biomedicum Helsinki, Helsinki University Central Hospital and University of Helsinki, Helsinki, Finland
    Prostate 68:945-54. 2008
    ..We have previously shown that seminal fluid contains both active and inactive, internally cleaved forms of PSA. The precise structural differences between these isoforms and their function are not known...
  13. ncbi Loss of endothelial Tie1 receptor impairs lymphatic vessel development-brief report
    Gabriela D'Amico
    Molecular Cancer Biology Laboratory, Biomedicum Helsinki, Department of Pathology, Haartman Institute and Helsinki University Central Hospital, University of Helsinki, Helsinki, Finland
    Arterioscler Thromb Vasc Biol 30:207-9. 2010
    ..We tested the hypothesis that the swelling observed in Tie1 mutant embryos is associated with lymphatic vascular defects...
  14. ncbi Complex formation between human prostate-specific antigen and protease inhibitors in mouse plasma
    Can Hekim
    Department of Clinical Chemistry, Biomedicum Helsinki, University of Helsinki, Helsinki University Central Hospital, Helsinki, Finland
    Prostate 70:482-90. 2010
    ..To justify the use of mouse models for evaluation of the function of PSA and for studies on therapeutic modalities based on modulation of PSA activity, it is important to know whether PSA complexation is similar in mouse and man...
  15. ncbi Gene expression changes associated with the anti-angiogenic activity of kallikrein-related peptidase 3 (KLK3) on human umbilical vein endothelial cells
    Johanna M Mattsson
    Department of Clinical Chemistry, Biomedicum Helsinki, University of Helsinki and Helsinki University Central Hospital, 00014 University of Helsinki, Finland
    Biol Chem 389:765-71. 2008
    ....
  16. ncbi A tumor-homing peptide with a targeting specificity related to lymphatic vessels
    Pirjo Laakkonen
    Cancer Research Center, The Burnham Institute, La Jolla, California, USA
    Nat Med 8:751-5. 2002
    ..These results suggest that tumor lymphatics carry specific markers and that it may be possible to specifically target therapies into tumor lymphatics...
  17. ncbi Nanocrystal targeting in vivo
    Maria E Akerman
    Cancer Research Center, The Burnham Institute, 10901 North Torrey Pines Road, La Jolla, CA 92037, USA
    Proc Natl Acad Sci U S A 99:12617-21. 2002
    ..These results encourage the construction of more complex nanostructures with capabilities such as disease sensing and drug delivery...
  18. ncbi Blocking VEGFR-3 suppresses angiogenic sprouting and vascular network formation
    Tuomas Tammela
    Molecular Cancer Biology Laboratory and Ludwig Institute for Cancer Research, Biomedicum Helsinki and the Haartman Institute University of Helsinki, PO Box 63 Haartmaninkatu 8, 00014 Helsinki, Finland
    Nature 454:656-60. 2008
    ..Our results implicate VEGFR-3 as a regulator of vascular network formation. Targeting VEGFR-3 may provide additional efficacy for anti-angiogenic therapies, especially towards vessels that are resistant to VEGF or VEGFR-2 inhibitors...
  19. ncbi VEGFR-3 expression is restricted to blood and lymphatic vessels in solid tumors
    Tatiana V Petrova
    Cancer Cell 13:554-6. 2008
  20. ncbi Stage-specific vascular markers revealed by phage display in a mouse model of pancreatic islet tumorigenesis
    Johanna A Joyce
    Department of Biochemistry and Biophysics, Diabetes and Comprehensive Cancer Centers, University of California, San Francisco, 513 Parnassus Avenue, San Francisco, CA 94143, USA
    Cancer Cell 4:393-403. 2003
    ..One peptide is homologous with pro-PDGF-B, which is expressed in endothelial cells, while its receptor is expressed in pericytes...
  21. ncbi Antitumor activity of a homing peptide that targets tumor lymphatics and tumor cells
    Pirjo Laakkonen
    The Burnham Institute, La Jolla, CA 92037
    Proc Natl Acad Sci U S A 101:9381-6. 2004
    ..As LyP-1 affects the poorly vascularized tumor compartment, it may complement treatments directed at tumor blood vessels...
  22. ncbi Lymphatic neoangiogenesis in human kidney transplants is associated with immunologically active lymphocytic infiltrates
    Dontscho Kerjaschki
    Department of Pathology, Medical University of Vienna, Allgemeines Krankenhaus, Vienna, Austria
    J Am Soc Nephrol 15:603-12. 2004
    ....